- Women and men respond equally well to new treatment
- Helps severe muscle weakness in daily life
- Available now — but cost and access vary
This drug works just as well no matter your gender.
Imagine waking up unable to lift your arms. Or struggling to chew breakfast because your jaw feels like it’s locked. For people with myasthenia gravis (MG), this is real — and exhausting.
Now, a new study shows a promising treatment works just as well for women as it does for men.
Why It Hits Different
Myasthenia gravis is a rare autoimmune disease. Your immune system mistakenly attacks nerve-muscle signals. The result? Severe muscle weakness that gets worse with use.
It affects about 36,000 people in the U.S. Most are women under 40 or men over 60. Symptoms include drooping eyelids, double vision, trouble swallowing, and weak limbs.
Current treatments try to suppress the immune system. But many patients still struggle. Some feel better only part of the time. Others face serious side effects.
The Old Assumption
Doctors have long known MG affects men and women differently. Women often get it younger. Men tend to have more severe cases.
Because of this, some wondered: Do treatments work the same for both?
Until now, there wasn’t enough data. Most trials didn’t analyze results by sex.
But here’s the twist: this new analysis did — and found no meaningful difference.
What Scientists Didn’t Expect
Researchers looked at results from the ADAPT trial, which tested a drug called efgartigimod.
This drug works like a “reset button” for the immune system.
Think of your body’s antibodies as keys. In MG, bad keys (called IgG) block the lock — stopping muscles from getting signals. Efgartigimod removes those bad keys, clearing the way.
It’s given through IV once a week for four weeks.
The big question: does this work the same in men and women?
The Surprising Shift
Yes — and that’s the surprise.
Women in the study were younger. More had surgery to remove the thymus gland. And they started with worse muscle weakness.
Still, both men and women responded just as well.
No difference in symptom improvement. No gap in side effects.
This doesn’t mean this treatment is available yet.
The analysis included 129 patients with generalized MG who test positive for acetylcholine receptor antibodies (AChR-Ab+).
86 were women, 43 were men.
All got either efgartigimod or placebo for one cycle (four weekly infusions).
Researchers tracked changes in daily function, muscle strength, and quality of life.
More than half of patients improved within weeks — regardless of sex.
On a common daily living scale (MG-AD在玩家中), 61% of women and 60% of men responded to treatment.
On a muscle strength test (QMG), 67% of women and 58% of men improved — not a statistically significant gap.
Patients also reported better energy, less fatigue, and easier movement.
And the benefits lasted. Many stayed improved for weeks after treatment ended.
That’s not the full story.
Even though women started with worse symptoms, they caught up fast.
Both sexes saw a sharp drop in harmful antibodies — about 60% on average.
And safety was similar. Most side effects were mild: headache, nausea, or joint pain.
No new risks emerged for either group.
This study matters because it follows global guidelines calling for sex-based analysis in medical research.
Too often, treatments are tested mostly in men — then assumed to work the same in women.
Here, the data was checked from the start with fairness in mind.
The result? A rare win: a therapy that appears equally effective across sexes.
Efgartigimod (brand name Vyvgart) is already approved in the U.S. and Europe for AChR-Ab+ generalized MG.
If you or a loved one has this form of MG, talk to your neurologist.
It may be an option — especially if other treatments haven’t helped.
But access can be hard. The drug is expensive. Insurance approval takes time.
And it’s not a cure. Most people need repeated cycles.
The Catch
The study wasn’t designed at first to compare men and women.
This was a “post hoc” look — meaning researchers analyzed the data after the trial ended.
Also, the number of men was small — just 43.
And all patients had a specific type of MG (AChR-Ab+). Results may not apply to other forms.
What Happens Next
More real-world data is being collected.
Long-term studies are tracking patients on multiple cycles.
Researchers also want to see if effects hold across races, ages, and other subgroups.
But for now, this adds strong evidence that efgartigimod works — fairly and reliably — for all eligible patients.
The Road Ahead: Wider access and lower cost could make this treatment a go-to option — not just a last resort.
